Deenova Continues to Set Records in Its Market Growth in France, With 4 New Contracts Awarded by Leading French Hospitals
26.7.2022 07:00:00 EEST | Business Wire | Press release
Boosting its unstoppable rise in the French market, Deenova announces four new contract awards, for its pioneering and unrivaled D3 series. Three AIDE Pick and two AIDE Cut robots, Deenova’s D3 latest innovative solutions, has been awarded by the Center Hospitalier in Bagnères de Bigorre by winning the competitive UniHA tender. Simultaneously Deenova reports new RESAH contracts for its long established and market leading ACCED robot at University Hospital of Saint-Ètienne and at Center Hospitalier intercommunal de Poissy - Saint-Germain-en-Laye. Finally, Center Hospitalier de Tourcoing, existing Deenova Acced and ASTUS customer, confirms its trust in Deenova D3 solutions with 20 additional ASTUS secured cabinets, through the UniHA tendering.
Loïc Bessin, Managing Director of Deenova France, stated: " With these new contracts, we are now exceeding the bar of 100 Hospital Pharmacy automation solutions in France spread over more than 40 healthcare institutions, which makes Deenova by far the number 1 company in France, with our solutions referenced both at UniHA and RESAH.”
Christophe Jaffuel, Chief Commercial Officer of Deenova, added: "Those recent tender awards are extremely significant for us, not only they confirm our dominant market share in France, with a third year of very strong consecutive growth, but also the early acceptance of our recently launched modular AIDE product line, as well as the solidity of our partnerships with RESAH and UniHA. A positive trend, that we expect to continue in future.”
The Center Hospitalier of Bagnères de Bigorre is a HAS certified facility in the Pyrenees area, offering different services such as functional rehabilitation, general medicine, geriatric SSR, LTC, radiology and therapeutic education, as well as a nursing home.
The University Hospital of Saint-Ètienne is located in the heart of the Auvergne-Rhône-Alpes region. Its activities are organized around 16 poles and 68 services, with 1920 beds distributed over the 3 main sites. The 8,350 professionals care annually for over 170,000 patients in hospitalization and sessions and more than 500,000 in consultations.
The Center hospitalier intercommunal de Poissy - Saint-Germain-en-Laye is a member of the Groupement hospitalier de territoire des Yvelines Nord and is a public institution of reference in care, teaching, and research. It has specialized activity poles with quality of care and safety certified by HAS.
Centre Hospitalier de Tourcoing is a regional hospital with 780 beds, located in the northeast of the The European Metropolis of Lille and a group member of the GHT Lille Métropole Flandre Intérieure. It serves an area of 230 municipalities, with a population of 1.5 million inhabitants, and more than 2000 professionals working together to provide patient care.
Since 2004, Deenova is the undisputed leading supplier of mechatronics solutions for closed loop medications and RFID-based medical devices traceability in the healthcare industry.
Deenova’s unique, patented and fully integrated solutions ease the healthcare providers’ growing pressures to improve patient safety, reduce therapy errors, minimize waste and controlled substance diversion, contain costs, and diminish the gap between rising patient volume/acuity and scarce medical staff.
Deenova guarantees the simplification of all processes related to the management of medications and implantable/disposable medical devices with an expected cost savings range between 15% and 25%.
Please visit www.deenova.com for additional information on its market leading solutions.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220725005393/en/
Contact information
Contacts at Deenova:
Loïc Bessin, Christophe Jaffuel, Martina Buccianti
m.buccianti@deenova.com, +39 0523 785311
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
VerSprite Launches Fork and Knife: AI-Driven Threat Modeling and Adversarial Testing Built for the Speed of Modern Software27.6.2026 00:28:00 EEST | Press release
VerSprite, a global leader in risk-based threat modeling and the firm behind the PASTA (Process for Attack Simulation and Threat Analysis) methodology, today announced the general availability of Fork (www.forktm.com), a continuous application threat modeling platform, alongside Knife, an AI-led, human-on-the-loop adversarial testing platform for web applications and web API endpoints. Together, the two products operationalize a new model for product security—one where applications are securely designed, continuously modeled, and actively tested as part of the build process itself. The launch addresses a problem every security leader knows but few tools have solved: threat modeling is essential, never more so than in an AI-driven era, yet it has remained slow, manual, and anchored to frameworks designed for a different threat landscape. The problem: threat modeling matters more than ever—and most tools are stuck in 2005 For two decades, application threat modeling has leaned heavily on
Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility26.6.2026 23:30:00 EEST | Press release
Venture Global, Inc. (NYSE: VG) announced today that its wholly-owned subsidiary, Venture Global Shipping Holdings, LLC (“VGSH”), has entered into a Credit and Guaranty Agreement providing for a senior secured term loan facility (the “Facility”) in an aggregate principal amount of up to $1,500,000,000. The Facility will mature on June 26, 2032. Deutsche Bank and ING acted as coordinating lead arrangers for the Facility. ING also serves as facility agent and security trustee. VGSH intends to use the net proceeds from the Facility for general corporate purposes, including to reimburse Venture Global LNG, Inc. for payments previously made by it or its affiliates in connection with the acquisition of nine LNG carriers, funding certain reserve accounts, and paying transaction fees and expenses. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (“LNG”) with over 100 MTPA of capacity in production, construction, or development. Ven
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 21:00:00 EEST | Press release
Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solution – uses digital twin technology to identify vulnerable customers and recommend explainable next-best actions for fro
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom